KANT
Price
$0.35
Change
+$0.02 (+6.06%)
Updated
Apr 2 closing price
Capitalization
4.34M
MDGL
Price
$334.60
Change
+$10.62 (+3.28%)
Updated
Apr 2 closing price
Capitalization
7.39B
40 days until earnings call
Ad is loading...

KANT vs MDGL

Header iconKANT vs MDGL Comparison
Open Charts KANT vs MDGLBanner chart's image
Kineta
Price$0.35
Change+$0.02 (+6.06%)
Volume$3.59K
Capitalization4.34M
Madrigal Pharmaceuticals
Price$334.60
Change+$10.62 (+3.28%)
Volume$365.42K
Capitalization7.39B
KANT vs MDGL Comparison Chart
Loading...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KANT vs. MDGL commentary
Apr 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KANT is a Hold and MDGL is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 03, 2025
Stock price -- (KANT: $0.35 vs. MDGL: $334.60)
Brand notoriety: KANT and MDGL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KANT: 25% vs. MDGL: 71%
Market capitalization -- KANT: $4.34M vs. MDGL: $7.39B
KANT [@Biotechnology] is valued at $4.34M. MDGL’s [@Biotechnology] market capitalization is $7.39B. The market cap for tickers in the [@Biotechnology] industry ranges from $308.32B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KANT’s FA Score shows that 1 FA rating(s) are green whileMDGL’s FA Score has 1 green FA rating(s).

  • KANT’s FA Score: 1 green, 4 red.
  • MDGL’s FA Score: 1 green, 4 red.
According to our system of comparison, both KANT and MDGL are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MDGL’s TA Score shows that 3 TA indicator(s) are bullish.

  • MDGL’s TA Score: 3 bullish, 4 bearish.

Price Growth

KANT (@Biotechnology) experienced а +14.47% price change this week, while MDGL (@Biotechnology) price change was +0.23% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -5.26%. For the same industry, the average monthly price growth was -7.43%, and the average quarterly price growth was -11.99%.

Reported Earning Dates

MDGL is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Biotechnology (-5.26% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDGL($7.39B) has a higher market cap than KANT($4.34M). MDGL YTD gains are higher at: 8.436 vs. KANT (1.050). KANT has higher annual earnings (EBITDA): -20.45M vs. MDGL (-450.12M). MDGL has more cash in the bank: 926M vs. KANT (900K). KANT has less debt than MDGL: KANT (710K) vs MDGL (120M). MDGL has higher revenues than KANT: MDGL (180M) vs KANT (0).
KANTMDGLKANT / MDGL
Capitalization4.34M7.39B0%
EBITDA-20.45M-450.12M5%
Gain YTD1.0508.43612%
P/E RatioN/AN/A-
Revenue0180M-
Total Cash900K926M0%
Total Debt710K120M1%
FUNDAMENTALS RATINGS
KANT vs MDGL: Fundamental Ratings
KANT
MDGL
OUTLOOK RATING
1..100
6576
VALUATION
overvalued / fair valued / undervalued
1..100
32
Undervalued
70
Overvalued
PROFIT vs RISK RATING
1..100
10028
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
6342
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KANT's Valuation (32) in the null industry is somewhat better than the same rating for MDGL (70) in the Pharmaceuticals Other industry. This means that KANT’s stock grew somewhat faster than MDGL’s over the last 12 months.

MDGL's Profit vs Risk Rating (28) in the Pharmaceuticals Other industry is significantly better than the same rating for KANT (100) in the null industry. This means that MDGL’s stock grew significantly faster than KANT’s over the last 12 months.

MDGL's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as KANT (100) in the null industry. This means that MDGL’s stock grew similarly to KANT’s over the last 12 months.

MDGL's Price Growth Rating (42) in the Pharmaceuticals Other industry is in the same range as KANT (63) in the null industry. This means that MDGL’s stock grew similarly to KANT’s over the last 12 months.

MDGL's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as KANT (100) in the null industry. This means that MDGL’s stock grew similarly to KANT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MDGL
RSI
ODDS (%)
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
82%
Momentum
ODDS (%)
Bearish Trend 1 day ago
83%
MACD
ODDS (%)
Bearish Trend 1 day ago
82%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
77%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
76%
Advances
ODDS (%)
Bullish Trend 11 days ago
78%
Declines
ODDS (%)
Bearish Trend 9 days ago
81%
BollingerBands
ODDS (%)
N/A
Aroon
ODDS (%)
Bullish Trend 1 day ago
62%
View a ticker or compare two or three
Ad is loading...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SMC36.813.56
+10.71%
Summit Midstream Corporation
TEAM223.967.55
+3.49%
Atlassian Corp
VRNA60.291.75
+2.99%
Verona Pharma plc
APOG48.001.30
+2.78%
Apogee Enterprises
FTEK1.00N/A
-0.50%
Fuel Tech

KANT and

Correlation & Price change

A.I.dvisor indicates that over the last year, KANT has been loosely correlated with MDGL. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if KANT jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KANT
1D Price
Change %
KANT100%
+7.22%
MDGL - KANT
62%
Loosely correlated
+3.28%
VRPX - KANT
48%
Loosely correlated
-4.69%
SLNO - KANT
45%
Loosely correlated
+7.93%
VKTX - KANT
35%
Loosely correlated
+7.40%
CELC - KANT
34%
Loosely correlated
+0.75%
More